321 related articles for article (PubMed ID: 31590683)
1. Epigenetic synthetic lethality approaches in cancer therapy.
Yang H; Cui W; Wang L
Clin Epigenetics; 2019 Oct; 11(1):136. PubMed ID: 31590683
[TBL] [Abstract][Full Text] [Related]
2. Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism.
Morel D; Almouzni G; Soria JC; Postel-Vinay S
Ann Oncol; 2017 Feb; 28(2):254-269. PubMed ID: 28426098
[TBL] [Abstract][Full Text] [Related]
3. Identifying synthetic lethal targets using CRISPR/Cas9 system.
Dhanjal JK; Radhakrishnan N; Sundar D
Methods; 2017 Dec; 131():66-73. PubMed ID: 28710008
[TBL] [Abstract][Full Text] [Related]
4. A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality.
Parameswaran S; Kundapur D; Vizeacoumar FS; Freywald A; Uppalapati M; Vizeacoumar FJ
Trends Cancer; 2019 Jan; 5(1):11-29. PubMed ID: 30616753
[TBL] [Abstract][Full Text] [Related]
5. Exploiting epigenetic vulnerabilities in solid tumors: Novel therapeutic opportunities in the treatment of SWI/SNF-defective cancers.
Chabanon RM; Morel D; Postel-Vinay S
Semin Cancer Biol; 2020 Apr; 61():180-198. PubMed ID: 31568814
[TBL] [Abstract][Full Text] [Related]
6. Synthetic Lethality - Its Current Application and Potential in Oncological Treatment.
Bortlíková L; Müller P; Vojtěšek B; Rak V; Svoboda M
Klin Onkol; 2019; 32(Supplementum 3):19-24. PubMed ID: 31627702
[TBL] [Abstract][Full Text] [Related]
7. Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation.
Topatana W; Juengpanich S; Li S; Cao J; Hu J; Lee J; Suliyanto K; Ma D; Zhang B; Chen M; Cai X
J Hematol Oncol; 2020 Sep; 13(1):118. PubMed ID: 32883316
[TBL] [Abstract][Full Text] [Related]
8. ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies.
Caumanns JJ; Wisman GBA; Berns K; van der Zee AGJ; de Jong S
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):176-184. PubMed ID: 30025943
[TBL] [Abstract][Full Text] [Related]
9. Synthetic Lethality and Cancer - Penetrance as the Major Barrier.
Ryan CJ; Bajrami I; Lord CJ
Trends Cancer; 2018 Oct; 4(10):671-683. PubMed ID: 30292351
[TBL] [Abstract][Full Text] [Related]
10. Synthetic lethality guiding selection of drug combinations in ovarian cancer.
Heinzel A; Marhold M; Mayer P; Schwarz M; Tomasich E; Lukas A; Krainer M; Perco P
PLoS One; 2019; 14(1):e0210859. PubMed ID: 30682083
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9 for cancer research and therapy.
Zhan T; Rindtorff N; Betge J; Ebert MP; Boutros M
Semin Cancer Biol; 2019 Apr; 55():106-119. PubMed ID: 29673923
[TBL] [Abstract][Full Text] [Related]
12. [Synthetic lethality as a functional tool in basic research and in anticancer therapy].
Toma M; Skorski T; Sliwiński T
Postepy Hig Med Dosw (Online); 2014 Sep; 68():1091-103. PubMed ID: 25228518
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9-Mediated Genome Editing of Epigenetic Factors for Cancer Therapy.
Yao S; He Z; Chen C
Hum Gene Ther; 2015 Jul; 26(7):463-71. PubMed ID: 26075804
[TBL] [Abstract][Full Text] [Related]
14. Application of the concept synthetic lethality toward anticancer therapy: a promise fulfilled?
Canaani D
Cancer Lett; 2014 Sep; 352(1):59-65. PubMed ID: 23962561
[TBL] [Abstract][Full Text] [Related]
15. Current views on inducing synthetic lethal RNAi responses in the treatment of cancer.
Kacsinta AD; Dowdy SF
Expert Opin Biol Ther; 2016; 16(2):161-72. PubMed ID: 26630128
[TBL] [Abstract][Full Text] [Related]
16. DNA Double Strand Break Repair - Related Synthetic Lethality.
Toma M; Skorski T; Sliwinski T
Curr Med Chem; 2019; 26(8):1446-1482. PubMed ID: 29421999
[TBL] [Abstract][Full Text] [Related]
17. Biology and Development of DNA-Targeted Drugs, Focusing on Synthetic Lethality, DNA Repair, and Epigenetic Modifications for Cancer: A Review.
Watanabe K; Seki N
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255825
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic based synthetic lethal strategies in human cancers.
Gao A; Guo M
Biomark Res; 2020; 8():44. PubMed ID: 32974031
[TBL] [Abstract][Full Text] [Related]
19. Remodeling the cancer epigenome: mutations in the SWI/SNF complex offer new therapeutic opportunities.
Orlando KA; Nguyen V; Raab JR; Walhart T; Weissman BE
Expert Rev Anticancer Ther; 2019 May; 19(5):375-391. PubMed ID: 30986130
[TBL] [Abstract][Full Text] [Related]
20. Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma
Ali R; Al-Kawaz A; Toss MS; Green AR; Miligy IM; Mesquita KA; Seedhouse C; Mirza S; Band V; Rakha EA; Madhusudan S
Cancer Res; 2018 Dec; 78(24):6818-6827. PubMed ID: 30297533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
